Vima Therapeutics
Last verified 2026-05-19. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $40.0Mattributed |
|---|---|
| Latest round | series-a, $40.0M, 2026-03-10attributed |
| Founded | 2023 |
| Headquarters | Cambridge |
| Industry | healthcare |
| Stage | series-a |
| Website | vimatx.com |
Vima Therapeutics is a biopharma developing an oral therapy for movement disorders, starting with dystonia and Parkinson's. It serves patients with these conditions, which affect over a million people in the US. Its approach targets the underlying disease biology, and it is running the Stride dystonia study.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-03-10 | series-a | $40.0M | undisclosed |
Detected tech stack
Cloudflare, WordPress, Yoast SEO 27.6, Google Analytics, Google Tag Manager, Slick, jQuery Migrate 3.4.1, DoubleClick Floodlight, Cloudflare Bot Management, WP Engine, PHP, MySQL
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series A, $40.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $40.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | vimatx.com, read 2026-05-19 |
| Description | self-reported | vimatx.com, read 2026-05-19 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.